PURPOSE Recent evidence supports a signifi cant association between the intake of dietary fi ber and levels of infl ammatory markers. The objective of this study was to determine whether daily fi ber supplementation would reduce levels of infl ammatory markers.
INTRODUCTION
I nfl ammation and dietary factors play important roles in cardiovascular risk. [1] [2] [3] [4] [5] [6] Diets high in fi ber have been particularly associated with lower cardiovascular risk. 5, 6 Epidemiologic data also have shown an association between elevation of C-reactive protein (CRP) levels and cardiovascular risk in people with and without a history of heart disease. 1, 7 Elevated CRP levels are a common feature of obesity and also have been linked to insulin resistance, diabetes, the metabolic syndrome, hypertension, and other risk factors for cardiovascular diseases. [8] [9] [10] [11] [12] [13] [14] A recent update of the American Heart Association dietary guidelines emphasizes a high-fi ber diet and consumption of 25 to 30 g of fi ber per day. 15 Recent evidence supports a signifi cant association between the intake of dietary fi ber and CRP. 16 A previous study examined the relation of dietary fi ber to levels of CRP among adults with diabetes, hypertension, or obesity in the National Health and Nutrition Examination Survey (NHANES) and found an average intake of 13.5g of dietary fi ber per day. 14 In that
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study, after controlling for demographic factors, body mass index (BMI), cardiovascular risk factors, and total caloric intake, participants in the lowest quartile of fi ber consumption with 2 or more risk conditions had an increased risk of elevated CRP (odds ratio [OR] 2.25; 95% confi dence interval [CI], 1.38-3.67) compared with those in the highest quartile of fi ber consumption. 14 Another recent study 17 that examined 524 subjects with multiple measurements of CRP and dietary factors also observed an inverse association between intake of total dietary fi ber and CRP levels in both cross-sectional and longitudinal analyses (P <.05). The likelihood of elevated CRP levels was 63% lower (OR, 0.37; 95% CI, 0.16-0.87) in participants in the highest quartile of total fi ber intake than in participants in the lowest quartile. 17 These studies are consistent but rely on cross-sectional or cohort analyses. A recent randomized trial of dietary fi ber showed no signifi cant relationship between the dietary fi ber intervention and CRP concentrations except in a subgroup of lean normotensive individuals. 18 Consequently, the impact of dietary fi ber or fi ber supplementation on infl ammation is unclear, particularly as an intervention among overweight or obese individuals who have higher cardiovascular risk. 19, 20 A prospective trial of fi ber supplementation to investigate the effects suspected from epidemiologic studies was warranted according to the emerging evidence. 13, 16, 18 In the current study, we set out to examine the impact of 3 months of psyllium fi ber supplementation on CRP and other infl ammatory markers in 162 overweight or obese adults.
METHODS
This study was a randomized controlled trial of fi ber supplementation at 2 doses (14 g/d and 7 g/d) compared with no supplement in 162 adult volunteers aged 40 to 65 years. The study was approved by the Institutional Review Board at the Medical University of South Carolina (MUSC), Charleston, and registered at clinicaltrials.gov (NCT00085800). The study was performed at the General Clinical Research Center (GCRC) at MUSC and approved by the GCRC Advisory Committee. An external data safety-monitoring board reviewed progress regularly throughout the trial. The trial was designed to have 80% power to detect standardized mean differences in CRP concentrations between the high-fi ber supplementation and control groups of approximately 0.6 mg/L using 43 subjects per group.
Participants were eligible if they were aged 40 to 64 years, gave informed consent, had a BMI of greater than 25 kg/m 2 , and had stable weight for the last 3 months (no change more than ± 5%). In addition, participants needed to have a CRP concentration of greater than 3.0 mg/L for women and greater than 2.0 mg/L for men to account for the differences in CRP levels by sex (median CRP = 3.3 mg/L in women vs 1.8 mg/L in men; P <.001). 21, 22 The study focused on individuals with a BMI of greater than 25 kg/m 2 because of the impact of BMI on CRP levels and the great proportion of individuals who are overweight or obese and who have elevated CRP levels. 8 Patients were excluded for pregnancy, regular use of a fi ber supplement of more than 4 g/d, a history of known cardiovascular disease (including myocardial infarction, stroke, congestive heart failure, or history of revascularization procedure [bypass, angioplasty, or stent placement]), uncontrolled hypertension (>170/95 mm Hg), electrocardiographic evidence of ischemia or infarction, recent (within 90 days) or planned participation in a formal weight loss program, and a history of infl ammatory disease, including collagen vascular disease, infl ammatory arthritis, recent serious infection, or other infl ammatory condition. Patients were permitted to continue taking current medications, including aspirin, coenzyme A reductase inhibitors, or thiazolidinediones, but were allowed no new medication within 90 days and no change in dosage for the last 30 days.
After a screening visit at the GCRC to determine eligibility, eligible patients were randomized using an online randomization program kept confi dential from the primary investigators. Participants were assigned to either the low-dose psyllium group (7 g/d), the highdose psyllium group (14 g/d), or control (no psyllium) ( Figure 1 ). Study investigators (except the research coordinator) were blinded to assignments and did not see study data until the trial was completed; the participants were not blinded to assignment group. After a baseline laboratory evaluation, history, and physical examination, the patients were scheduled to return to the GCRC in 1 month, and again in 3 months for follow-up. Measurements of CRP (highsensitivity [hsCRP]) concentration, white blood cell (WBC) count, fi brinogen level, and interleukin-6 (IL-6) concentration were obtained at baseline, because previous research found them to be infl ammatory markers and associated to some degree with cardiovascular risk.
1,4,23,24 CRP, WBC, IL-6, and fi brinogen values were also obtained at the fi nal 3-month follow-up visit.
Participants were given fi ber supplements in powder form in packets containing 3.5 g of psyllium fi ber each. The low-fi ber supplementation group took 2 packets each day between meals mixed in water; the high-fi ber supplementation group took 4 packets each day spread throughout the day between meals. Participants in the intervention were instructed to take 1 packet daily in no-pulp orange juice to match control participants, who were told to drink 1 8-ounce glass of no-pulp orange juice daily. Participants on fi ber supple-
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mentation took the remaining doses of psyllium mixed only with water. Compliance was assessed at each visit using fi ber packet counts.
To determine eligibility for the study, blood samples for CRP measurement were drawn using standard phlebotomy techniques and sent for analysis in the CLIA-certifi ed MUSC laboratory. Participants' serum CRP concentration was determined by a high-sensitivity method using the IMMAGE Immunochemistry System (Beckman Coulter, Brea, California). The IMMAGE CRP reagent is based on the highly sensitive near infrared particle immunoassay rate method. The analytical range for the IMMAGE system was 0.2 mg/L to 60 mg/L. For the primary outcome analyses for CRP levels, frozen sera from participants were sent as paired samples (baseline and 3 months) to an outside reference laboratory (Emory General Clinical Research Core Laboratory, Atlanta, Georgia), and samples were analyzed using a commercial ELISA kit from ALPCO Diagnostics (Salem, New Hampshire). For hsCRP determinations, frozen plasma samples were thawed at room temperature and centrifuged at 16,000 g for 10 minutes to remove any precipitate. Samples were diluted 1:1000, and hsCRP concentrations were measured, in duplicate, using the ELISA kit from ALPCO Diagnostics (assay sensitivity, 0.124 ng/mL; assay range,1.9-150 ng/mL).
For IL-6 measurements, blood was collected using standard phlebotomy techniques and frozen to -20ºC; paired samples were sent to Associated Regional and University Pathologists, Inc (ARUP) laboratories in Salt Lake City, Utah, and analyzed with an IMMU-LITE analyzer (Diagnostics Products Corporation, Los Angeles, Calif) using chemiluminescence technique 
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and a sequential immunometric assay. 25 The analytic range of the system was 5.0 to 1,000 pg/mL. Fibrinogen was determined in MUSC laboratories using the Clauss clotting method (STAR Diagnostics, Dallas, Texas). 26 WBC count was determined based on the optical scatter and fl uorescence technique (Cell-Dyne 4000, Abbott, Abbott Park, Illinois). 27 The primary analysis was intent-to-treat and focused on changes in the CRP level in the high-fi ber group compared with the changes in the control group during the 3-month study. The primary outcome of the study was change in CRP level from baseline to the fi nal month 3 visit. The primary comparison was between the mean changes from baseline to 3 months in the high-fi ber supplementation group compared with the control group at month 3 using the 2-sample t test. The intent-to-treat analysis included all participants for whom there were postbaseline values. Analysis was done using last value carried forward to account for missing values at the fi nal visit.
In secondary analyses, the mean change in CRP levels from baseline to 3 months also was compared between the low-fi ber supplementation group and control group. Because CRP levels are not normally distributed, differences in the natural log transformed CRP levels were also examined. Fibrinogen levels and WBC count also were compared using the same comparisons as for CRP levels. The level of detection for IL-6 was 2.0 pg/mL, and many of the participants had levels below the detection limit. As a result, for IL-6 groups were compared using the percentage of each group above and below the baseline median IL-6 concentration (median = 2.55 pg/mL). An analysis of protocol completers done separately from the main intent-to-treat analysis included participants who attended the fi nal visit, consumed at least 75% of the prescribed supplement, and did not add any medications known to affect infl ammation (statins, thiazolidinediones, and corticosteroids). Throughout the statistical analyses 2-sample t tests (or χ 2 for categorical variates) comparing the high-fi ber supplementation and control groups were the primary comparisons specifi ed in the protocol design. There was no prespecifi ed plan to adjust the type I error rate for this primary trial comparison of these 2 treatment arms. Statistical signifi cance was specifi ed in advance at an α of .05.
We conducted linear regression modeling of the effect of fi ber supplement group on the changes in infl ammatory markers. These regressions also incorporated BMI (kg/m 2 ) as a control factor. CRP was treated linearly and was log-transformed in separate regressions to account for skewness. In addition, we analyzed the response to fi ber supplementation according to baseline fi ber intake. We also stratifi ed the participants into those who were or were not taking stable doses of medications that might interfere with CRP levels (aspirin, statins, and glitazones) and analyzed change in CRP levels and other markers comparing the 2 groups.
RESULTS
The trial profi le and selection of participants are outlined in Figure 1 . Among the 420 adults screened for elevated CRP levels, 171 met entry criteria. Nine participants dropped out after the screening and before the baseline visit, leaving 162 who participated in the complete baseline evaluation. These 162 are referred to as "the randomized patient population" in Table 1 . 
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Within this group, 4 failed to attend any further visits, leaving 158 participants in the intent-to treat group. There were 5 participants (all in the high-fi ber supplementation group) who attended the 1-month visit, but not the 3-month visit; thus, data from the 1-month visit was carried forward and used as the fi nal data for these participants in the intent-to-treat analyses. (Analyses excluding these 5 patients also produced the same fi ndings but are not reported for sake of brevity.) Participants who did not show for the 3-month follow-up visit (5), were less than 75% compliant with the fi ber supplementation regimen (15) , or added medications that could potentially decrease infl ammatory markers (6) were excluded from the analysis of protocol completers (132 participants). Among those who added new medications, 4 added atorvastatin, 1 added rosiglitazone, and 1 added prednisone. The 3 study groups were balanced for demographic and clinical characteristics including age, sex, race, smoking status, and BMI (Table 1 ). There were also no signifi cant differences in baseline characteristics (fi brinogen level, WBC count, or CRP concentration between either of the 2 treatment groups receiving fi ber supplements and the control group (P >.05). Compliance rates were not different between the low-fi ber and high-fi ber supplementation groups (P = .94). There were no signifi cant adverse events attributed to treatment in any of the intervention groups.
In the intent-to-treat analysis, there were no signifi cant differences between either of the 2 treatment groups and the control group in the amount of change in CRP levels, fi brinogen levels, or WBC counts (P >.05) ( Table 2 ). In the secondary analysis of study protocol completers (attended visit 3, ≥75% compliant, no additions to medication), there also were no signifi cant differences between either of the treatment groups and the control group for changes in any of the infl ammatory marker outcomes except for fi brinogen (Table 3 ). The distribution of IL-6 levels was also not signifi cantly different between the treatment groups, except that a lower percentage of participants in the low-fi ber group had IL-6 levels above the median than either of the other 2 groups (χ 2 ; P = .043) ( Table 4 ). The high-fi ber supplementation group did have a signifi cant decrease in mean fi brinogen levels (-6 mg/L [-0.18 μmol/L] compared with 13 mg/L [0.38 μmol/L] in the control group; P <.05).
In adjusted linear regression analyses, after controlling for BMI, the high-fi ber supplementation group showed a signifi cant decrease in fi brinogen levels compared with the control group (P = .03). No other 
infl ammatory markers showed any statistically signifi cant differences between intervention and control groups after 3 months. In further regression analyses taking into account baseline fi ber intake, there were no differences in CRP levels from baseline to 3 months between treatment groups. Further, no differences were seen between groups when groups were stratifi ed according to whether they were taking stable doses of medications that might interfere with CRP levels.
DISCUSSION
In this randomized trial of psyllium fi ber supplementation among overweight and obese adults, there were no signifi cant reductions in CRP levels from baseline to 3 months in the high-fi ber group compared with controls in the intent-to-treat analysis. In secondary analyses of IL-6 concentrations, WBC counts, and fi brinogen levels, there were no differences between treatment groups. In further analyses of protocol completers, a small reduction in fi brinogen level was found from baseline to 3 months in the high-fi ber supplementation group compared with the control group, which in the context of other study results is likely not clinically signifi cant. The trial was conducted at a single study center but had a racially diverse population with substantial representation of both whites and blacks (approximately 50% each). Analyses stratifi ed according to BMI, baseline fi ber intake, or use of other medications also yielded no statistically signifi cant differences in infl ammatory markers between fi ber supplementation and control groups at 3 months. These trial results contrast with previous crosssectional and cohort analyses that suggested an association of dietary fi ber intake with CRP concentration. 16, 17 The results are consistent with the fi ndings of a recent clinical trial that found little change in CRP levels among obese hypertensive individuals taking a psyllium fi ber supplement, but that previous trial was small (N = 35) and supplementation was for only 3 weeks. 18 The current results add confi rmation to the notion that fi ber supplementation with psyllium does not signifi cantly reduce CRP levels in overweight or obese individuals.
Although disappointing, the current fi ndings may not be unprecedented when examining the evidence from other dietary supplements trials that followed epidemiological evidence of dietary intake and a health outcome. For example, oxidative stress is associated with cardiovascular disease, and epidemiological evidence suggested that individuals with diets high in fruits and vegetables or antioxidants had lower rates of cardiovascular disease. When randomized clinical trials were conducted to examine the impact of antioxidants. such as vitamin E, 28, 29 on cardiovascular disease, however, the interventions were not successful. 30 These results do not suggest that the epidemiological evidence is faulty or that the underlying mechanism regarding oxidative stress and cardiovascular disease needed to be modifi ed; they suggest that perhaps isolating vitamin E from one's diet into a supplement may not represent the behavior of a diet high in fruits and vegetables. In a similar way, the current fi ndings do not negate the importance of a diet naturally high in fi ber, 31, 32 but they do suggest that taking a psyllium supplement may not be an effective way to reduce infl ammation and presumably risk of cardiovascular disease.
There are several limitations to this study that may suggest alternative explanations. First, this study used only one type of fi ber (psyllium) as the intervention supplement, and it was not blinded for the participants. Further, although both a high-and low-fi ber dose was included in the study, it is possible that other types of fi ber, such as pectin or oats, could have yielded different results. Psyllium seemed to be the ideal choice because of its tolerability and that psyllium supplements did result in some lowering of CRP levels among lean individuals. 18 Second, the length of the study may have affected the impact of the fi ber supplementation intervention. It is possible that fi ber supplementation requires longer than the 3 months allocated in this study to have a substantial effect on infl ammation. Third, patient characteristics other than BMI may have infl uenced the effect of the intervention across the groups. Even so, the randomization schedule and the lack of differences between the groups suggest that known and unknown characteristics were randomly distributed across the groups. Finally, although the study was designed to have 80% power to detect a 20% change in CRP levels, the differences between groups did not meet this criterion, and the study may have been underpowered. There was, however, no trend or slope seen in the current study to hint at undetected changes, and the previous study of psyllium supplementation also found only modest changes (10%) in obese persons 18 ; thus the current negative study result is fairly well substantiated.
In conclusion, the current study did not fi nd a signifi cant impact of psyllium fi ber supplementation on CRP levels or other infl ammatory markers. This fi nding does not negate the epidemiologic evidence that dietary fi ber is a factor in reducing infl ammation 16 or the risk of cardiovascular disease, 33 but it does suggest that fi ber supplementation with psyllium does not replicate the results seen with a diet naturally high in fi ber. Further research with other types of fi ber or with combinations of nutrients may be warranted.
